UNSPSC 51273940: Epinephrine/lidocaine/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273940 Epinephrine/lidocaine/sodium chloride (Commodity) covers emergency pharmaceuticals, naloxone products, and related drug deactivation systems that state and local health and human services agencies procure to support public health and community safety initiatives. State and local solicitations under this code reflect procurement of both branded and generic pharmaceutical products through competitive bidding processes, cooperative purchasing vehicles, and exploratory market-intelligence requests. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and government facilities. The work encompasses direct pharmaceutical supply, management of opioid-response medications, and drug deactivation systems for distribution to community health buildings and participating state and local government sites.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023, and potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling state interest in alternative pharmaceutical supply models. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must maintain relationships with authorized wholesalers, comply with cGMP and DSCSA requirements, and accept a 3 percent administrative fee on purchases.